Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed colorectal cancer
• * Biopsy-accessible metastatic disease
• Measurable disease
• No CNS metastases
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• ECOG 0-2
• Life expectancy
• At least 3 months
• Hematopoietic
• WBC ≥ 4,000/mm\^3 OR
• Absolute neutrophil count ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• Hemoglobin ≥ 10 g/dL
• No bleeding disorder
• Hepatic
• Bilirubin ≤ 1.5 mg/dL
• Albumin ≥ 2.5 g/dL
• Renal
• Creatinine ≤ 1.5 mg/dL
• Urine protein:creatine ratio \< 1.0
• Cardiovascular
• Blood pressure ≤ 150/100 mmHg
• No arterial thrombotic event within the past 6 months
• No New York Heart Association grade II-IV congestive heart failure
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 1 month after completion of study treatment
• No other malignancy within the past 3 years except nonmelanoma skin cancer, carcinoma in situ of the cervix, or other malignancy with \< 10% chance of relapse within 3 years
• No uncontrolled infection
• No severe uncontrolled illness that would preclude study participation
• No peripheral neuropathy interfering with function
• No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
• No serious non-healing wound, ulcer, or bone fracture
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• No concurrent immunotherapy
• No concurrent sargramostim (GM-CSF)
• Chemotherapy
• No prior chemotherapy, including oxaliplatin, for metastatic disease
• Prior adjuvant oxaliplatin allowed provided disease progressed \> 12 months after completion of oxaliplatin
• At least 3 weeks since prior cytotoxic chemotherapy (6 weeks for mitomycin or nitrosoureas)
• * No more than 2 courses of prior mitomycin
• No concurrent chemotherapy
• Endocrine therapy
• No concurrent anticancer hormonal therapy
• Radiotherapy
• At least 2 weeks since prior radiotherapy
• No prior radiotherapy to \> 15% of bone marrow
• No concurrent radiotherapy
• Surgery
• At least 4 weeks since prior major surgery
• At least 1 week since prior minor surgery
• Other
• Recovered from prior therapy
• No prior epidermal growth factor receptor inhibitor therapy
• No other concurrent antineoplastic or antitumor therapy
• No other concurrent investigational agents